What’s the new advice about puberty blockers for trans and gender-diverse children?

Detailed summary
The draft national advice says treatment can be considered for some trans and non-binary kids. But Queensland and the NT have ruled out lifting their restrictions.
Australia’s leading health research body yesterday released draft advice on puberty suppressants, also known as puberty blockers. These medicines should be available for some young people under 18 with “gender incongruence”, the National Health and Medical Research Council (NHMRC) says.
The review comes amid growing international efforts to restrict young people’s access to gender-affirming care.
In January 2025, Queensland stopped new patients in its public health system from starting puberty suppressants or gender-affirming hormones. The NHMRC review was announced three days later.
Restrictions have also been introduced or proposed in the United Kingdom, Finland, Sweden, Argentina, Brazil, Turkey and parts of Canada. In the United States, many states have banned these treatments for minors. New Zealand introduced restrictions in 2025, but its High Court overturned them last month.
So, what is gender incongruence, what does the draft advice actually say, and why is there so much disagreement?
Puberty suppressants have been prescribed to transgender and gender-diverse young people for decades.
They work by temporarily suppressing the hormonal signals that drive puberty, reducing the body’s production of oestrogen or testosterone.
Puberty suppressants have been used to treat early (precocious) puberty since the 1980s.
Related medicines are also used to treat endometriosis and some hormone-sensitive cancers.
Opening of the article, excerpted from The Conversation AU. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (theconversation.com)




